Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS2687367 A
Publication typeGrant
Publication dateAug 24, 1954
Filing dateMay 5, 1952
Priority dateMay 5, 1952
Publication numberUS 2687367 A, US 2687367A, US-A-2687367, US2687367 A, US2687367A
InventorsBurrin Philo L
Original AssigneeLilly Co Eli
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Medicinal tablet containing identification fragments
US 2687367 A
Abstract  available in
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

P. l.. BURRIN 2,687,367

FICATION FRAGMENTS Aug. 24, 1954 MEDICINAL TABLET CONTAINING IDENTI Filed May 5, 1952 Patented Aug. 24, 1954 MEDICINAL TABL IDENTIFICATIO ET CONTAINING N FRAGMENTS Philo L. Burrin, Indianapolis, Ind., assigner to Eli Lilly and Company,

corporation of Indiana AApplication May 5, 1952, Serial No. 286,157

. 3 Claims.

This invention relates to a protective identification of ethical drugs such ,asy tablets, capsules and the like and to a method of producing such medications having such protective identification.

In the practice of medicine it is customary, in many instances and for various reasons, to conceal from the patient the name, nature and/or character of the medicament prescribed for the illness being treated. For this reason, the manufacturer of ethical drugs, cooperating with the medical profession, for the most part refrains from placing any mark or indicia on the medicine per se, i. e., upon the tablet, capsule, pill, or the like, the identification of the medicament and brand name being ahxed as by label to a bottle or other container in which such drug items are customarily packaged. This has sever-al disadvantages amongst which is the extreme disadvantage owing from an unscrupulous substitution or palming off of a possibly inferior substitute or unwanted or unprescribed tablet, pill or capsule for the particular ethical drug called for by the prescription.

It is an obj ect of the present invention to provide an ethical drug product such as a, pill, tablet, capsule lor lthe like which is secretively marked so as to be easily identifiable by the ethical drug manufacturer, his agent or representative, the druggist or physician, and yet which is not readily observable and remains relatively secret from the patient.

A further object of this invention is to provide anethical drug i-dentication means of the above character, which is simple, effective, easily accomplished oonformably to present day mass production methods and with but little additional expense.

Other objects of the invention will become apparent from -the following description, appended claims, and accompanying drawings wherein:

Fig. l is an enlarged side elevation, partly in section, of an uncoated medicinal base tablet of the character in which the invention may be embodied, and

Fig. 2 is a View similar the base tablet With the thereover.

The tablet I shown in Fig. 1 is of the usual ellipsoidal shape and of the customary form used generally by the pharmaceutical industry. It will be understood that the representation of a tablet for the embodiment of the invention is for illustrative purposes only and that the invention can as well nd us-e in the secretive identification of to Fig. 1 but showing usual coating applied Indianapolis, Ind., a

capsules, pills and other like items used in preparing medicaments for administration.

Generally speaking, the granulations (indicated by cross section lines .at I I in Figs. 1 and 2) composingr medicinal tablets are of a size ranging from 2000 to 3000 microns. Th-e invention comprises the thorough mixing of innocuous, inert, colored, fragments I 2 of gelatin, methyl cellulose, ethyl cellulose, sucrose or the like and of a size of the order of 250 to 840 microns into the granulation II constituting the tablet compound in such a manner as to yuniformly but randomly disperse the fragments completely and thoroughly throughout the compound. While methyl and/or ethyl cellulose fragments may 'be used, gelatin or sucrose fragments are preferred because the latter are assimilable or metabolizible in the human system. added in relatively small proportions to the total composition, i. e., the quantity of fragments ladded is from one to ten percent of the total composition. Following this the compound, with the colored fragments -thoroughly mixed therein, is compressed in the usual manner into the tablet form illustrated in Figs. 1 and 2 wherein it is observed that theV colored fragments are clearly visible over all surfaces of the base tablet I0 as well as the sectioned portion thereof. Fragments I2 are shown in the illustration as being the primary colors, red, blue and yellow. It will 'be course that any single color or combination of colors may be used and that the above selection is arbitrary and set forth merely for illustrative purposes.

Following the compression of the medicinal compound into tablet form as above described the base tablet I 0 has one or more coatings such applied completely thereover in the usual pensed.

Consequently, the patient that The fragments I2 are vision of the -colored gelatin fragments the pharmaceutical manufacturer or his field representative may readily ascertain whether a substitution or palming ofi of a possibly inferior or unwanted or unprescribed product for the particular manufacturers product has been or is being attempted to be effected as by simply removing a sufficient portion of the coating materials i5, i4, and I3 to expose at least a moderate sized surface portion of the base sectioning or breaking the tablet open to expose its interior. This will expose .the colored fragments to view and their particular size and color combination will readily identify the manufacturers product, Whereas upon applying the same test to a substitute product such fragments will be either entirely absent or not within the proper color combination to identify the product as being supplied by the particular manufacturer.

Hence it will be seen that I have provided by my invention a simple, inexpensive and secretive means of positively giving identification to ethical drugs in `tablet or like form and a method of making such tablets or the like Which is simply, efficiently and economically adaptable to the customary manufacturing methods and techniques employed by the pharmaceutical industry in the manufacture of such items. At the same time, my invention retains the product completely free of any suggestion to the ultimate consumer of the nature and/ or character of the medicament prescribed for any specific illness which is being ltreated thereby meeting the demands of the medical practitioner.

I claim:

1. As an article of manufacture, a medicinal base tablet having a coating exteriorly thereover and interiorly of said coating having its medicinal granulations uniformly flecked throughout with a dispersion of multi-colored, inert, harmless,

metabolizible, gelatin fragments, said colored fragments having been previously admixed with said granulations and being completely hidden by said coating but becoming readily visible upon removal of a portion of said coating sufficient to Itablet l or by simply expose a relatively small area of the surface of said base tablet or upon breaking said tablet open.

2. As an article of manufacture, a medicinal base tablet compressed of medicinal granules of a size of the order of from 2000 to 3000 microns, said tablet having a 1 to 10 percent proportion of its total composition of colored, inert, innocuous, contrasting colored, metabolizible, gelatin fragments of a size of the order of 250 to 840 microns thoroughly admixed with and uniformly dispersed at random -throughout said medicinal granules before their compression into tablet form, said fragments being visible on all exterior surfaces of the base tablet land on any surface thereof exposed by reason of sectionalizing said tablet, and a coating completely covering said base tablet and said contrasting colored fragments.

3. A medicinal tablet comprising an inner base having a coating applied completely thereover, said base having its medicinal granules thoroughly admixed with a portion of multi-colored, inert, metabolizible, gelatin particles in sufficient proportion With respect to said granule mass that following thorough admixing with said mass and upon being compressed therewith intoA said inner base, said particles are thoroughly and uniformly distributed surf acewise of and interiorly throughout said base, said dispersed, colored particles being completely covered by said coating and becoming readily visible upon breaking said tablet open or upon removal of a portion of said coating suicient to expose a relatively small area of the surface of the said base tablet.

lgeferences Cited in the le of this patent UNITED STATES PA'IENTS Number Name Date 1,134,156 Platen Apr. 6, 1915 1,148,621 Planten Aug. 3, 1915 2,410,110 Taylor Oct. 29, 1946 FOREIGN PATENTS Number Country Date 621,651 Great Britain Apr. 13, 1949

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US1134156 *Dec 3, 1914Apr 6, 1915Hermanus Rolff PlantenGelatin capsule.
US1148621 *Dec 9, 1914Aug 3, 1915Hermanus Rolff PlantenGelatin capsule.
US2410110 *Jan 14, 1943Oct 29, 1946Brewer & Company IncMethod of making tablets
GB621651A * Title not available
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3044938 *Jul 1, 1955Jul 17, 1962Sandoz Chemical Works IncSustained action pharmaceutical tablets
US3125490 *Aug 9, 1961Mar 17, 1964 Tablet with contrasting indicia and method
US3177820 *Mar 27, 1961Apr 13, 1965American Cyanamid CoTablet granulation apparatus
US4390452 *Aug 20, 1979Jun 28, 1983Minnesota Mining & Manufacturing CompanyMicroparticles with visual identifying means
US4432966 *Aug 31, 1982Feb 21, 1984Roussel-UclafCompressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
US4457907 *Aug 5, 1982Jul 3, 1984Clear Lake Development GroupComposition and method for protecting a therapeutic drug
US4661367 *Sep 27, 1985Apr 28, 1987Imperial Chemical Industries PlcProcess for the manufacture of colored intagliated articles
US5002775 *Mar 4, 1983Mar 26, 1991Sumitomo Chemical Company, LimitedTablets having clear impressed marks and method for making same
US5283065 *Mar 23, 1992Feb 1, 1994American Cyanamid CompanyControlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5431918 *Oct 30, 1992Jul 11, 1995Soremartec S.A.Breath mint configuration
US7720254Mar 13, 2007May 18, 2010Smi Holdings, Inc.Automatic microparticle mark reader
US7831042Mar 13, 2007Nov 9, 2010Smi Holdings, Inc.Three-dimensional authentication of microparticle mark
US7885428Dec 18, 2009Feb 8, 2011Smi Holdings, Inc.Automatic microparticle mark reader
US8033450Mar 13, 2007Oct 11, 2011Smi Holdings, Inc.Expression codes for microparticle marks based on signature strings
US8223964Oct 6, 2010Jul 17, 2012Smi Holdings, Inc.Three-dimensional authentication of mircoparticle mark
US8888005May 31, 2013Nov 18, 2014David ProkopUniquely identifiable drug dosage form units
US20060037222 *Dec 2, 2002Feb 23, 2006Dan HuntTaggants for products and method of taggant identification
U.S. Classification424/10.3, 424/465, 424/467, 424/472, 424/470
International ClassificationA61K9/20, A61K9/28
Cooperative ClassificationA61K9/28, A61K9/2072
European ClassificationA61K9/28, A61K9/20K